References
- Linton MF, Farese RV Jr, Young SG. Familial hypobetalipoproteinemia. J Lipid Res. 1993; 34(4): 521-541.
- Tarugi P, Averna M, Di Leo E, Cefalu AB, Noto D, Magnolo L, Cattin L, Bertolini S, Calandra S. (Author: all authors must be cited) Molecular diagnosis of hypobetalipoproteinemia: an ENID review. Atherosclerosis. 2007; 195(2): e19-27.
- Burnett JR, Hooper AJ. Common and rare gene variants affecting plasma LDL cholesterol. Clin Biochem Rev. 2008; 29(1): 11-26.
- Whitfield AJ, Barrett PH, van Bockxmeer FM, Burnett JR. Lipid disorders and mutations in the APOB gene. Clin Chem. 2004; 50(10): 1725-1732.
- Olofsson SO, Wiklund O, Boren J. Apolipoproteins A-I and B: biosynthesis, role in the development of atherosclerosis and targets for intervention against cardiovascular disease. Vasc Health Risk Manag. 2007; 3(4): 491-502.
- Schonfeld G. Familial hypobetalipoproteinemia: a review. J Lipid Res. 2003; 44(5): 878-883.
- Schonfeld G, Lin X, Yue P. Familial hypobetalipoproteinemia: genetics and metabolism. Cell Mol Life Sci. 2005; 62(12): 1372-1378.
- Elias N, Patterson BW, Schonfeld G. Decreased production rates of VLDL triglycerides and ApoB-100 in subjects heterozygous for familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol. 1999; 19(11): 2714-2721.
- Hooper AJ, van Bockxmeer FM, Burnett JR. Monogenic hypocholesterolaemic lipid disorders and apolipoprotein B metabolism. Crit Rev Clin Lab Sci. 2005; 42(5-6): 515-545.
- Amaro A, Fabbrini E, Kars M, Yue P, Schechtman K, Schonfeld G, Klein S. (Author: all authors must be cited) Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology. 2010; [Epub ahead of print].
- Sankatsing R, Fouchier S, de Haan S, Hutten B, de Groot E, Kastelein J, Stroes ES. Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol. 2005; 25(9): 1979-1984.
- Cohen J, Boerwinkle E, Mosley TJ, Hobbs H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006; 354(12): 1264-1272.
- Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning. A Laboratory Manual. Cold Spring Arbor: Cold Spring Laboratory; 1989.
- Knott T, Wallis S, Powell L, Pease R, Lusis A, Blackhart B, McCarthy BJ, Mahley RW, Levy-Wilson B, Scott J. Complete cDNA and derived protein sequence of human apolipoprotein B-100. Nucleic Acids Res. 1986; 14(18): 7501-7503.
- Tarugi P, Lonardo A, Ballarini G, Erspamer L, Tondelli E, Bertolini S, Calandra S. A study of fatty liver disease and plasma lipoproteins in a kindred with familial hypobetalipoproteinemia due to a novel truncated form of apolipoprotein B (APO B-54.5). J Hepatol. 2000; 33(3): 361-370.
- Tanoli T, Yue P, Yablonskiy D, Schonfeld G. Fatty liver in familial hypobetalipoproteinemia: roles of the APOB defects, intra-abdominal adipose tissue, and insulin sensitivity. J Lipid Res. 2004; 45(5): 941-947.
- Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006; 47(6): 1093-1100.
- Alberti KG, Zimmet P, Shaw J. The metabolic syndrome — a new worldwide definition. Lancet. 2005; 366(9491): 1059-1062.
- Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285(19): 2486-2497.